Earnest Partners LLC Has $7.53 Million Holdings in Hologic, Inc. (HOLX)

Earnest Partners LLC grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 205,158 shares of the medical equipment provider’s stock after buying an additional 4,152 shares during the quarter. Earnest Partners LLC owned approximately 0.07% of Hologic worth $7,527,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Janus Henderson Group PLC boosted its stake in Hologic by 15.5% during the third quarter. Janus Henderson Group PLC now owns 285,035 shares of the medical equipment provider’s stock valued at $10,458,000 after buying an additional 38,283 shares during the last quarter. Vident Investment Advisory LLC bought a new position in Hologic during the third quarter valued at approximately $387,000. Chevy Chase Trust Holdings Inc. lifted its stake in shares of Hologic by 1.4% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock valued at $8,975,000 after purchasing an additional 3,391 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Hologic in the 3rd quarter valued at approximately $3,669,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Hologic in the 3rd quarter valued at approximately $317,000. Institutional investors and hedge funds own 98.08% of the company’s stock.

In other news, VP Karleen Marie Oberton sold 1,256 shares of Hologic stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $39.29, for a total value of $49,348.24. Following the transaction, the vice president now directly owns 9,406 shares in the company, valued at approximately $369,561.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of Hologic stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. Insiders have sold a total of 28,833 shares of company stock worth $1,107,270 over the last 90 days. 0.79% of the stock is currently owned by company insiders.

Several research firms have recently issued reports on HOLX. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price target on shares of Hologic in a report on Friday, November 3rd. Goldman Sachs Group upgraded Hologic from a “buy” rating to a “conviction-buy” rating and increased their price target for the stock from $45.00 to $50.00 in a report on Friday. Cowen upgraded Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price target on the stock in a report on Monday. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price target (down from $48.00) on shares of Hologic in a report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $47.86.

Hologic, Inc. (NASDAQ:HOLX) opened at $43.82 on Tuesday. The company has a market capitalization of $11,768.93, a price-to-earnings ratio of 21.13, a price-to-earnings-growth ratio of 2.06 and a beta of 0.95. Hologic, Inc. has a fifty-two week low of $35.76 and a fifty-two week high of $46.80. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. The company had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. Hologic’s quarterly revenue was up 10.5% on a year-over-year basis. During the same period last year, the business posted $0.52 EPS. equities analysts predict that Hologic, Inc. will post 2.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://ledgergazette.com/2017/12/12/earnest-partners-llc-has-7-53-million-holdings-in-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply